表紙
市場調査レポート

ハウスダストダニアレルギー : パイプライン分析

House Dust Mite Allergy - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 246018
出版日 ページ情報 英文 53 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
ハウスダストダニアレルギー : パイプライン分析 House Dust Mite Allergy - Pipeline Review, H1 2016
出版日: 2016年02月24日 ページ情報: 英文 53 Pages
概要

ハウスダストダニアレルギーとは一般にハウスダストの中に生息する小さな虫に対する アレルギー反応であり、くしゃみや鼻水、鼻詰まり、鼻のかゆみ、目の痛みなどの症状があります。喘息や湿疹などの引き金になる可能性もあり、巻き上げられたハウスダストに近づくと悪化する場合があります。家族歴や年齢などが素因となり、治療法には抗ヒスタミン剤、充血緩和剤、コルチコステロイドの利用などがあります。

当レポートでは、世界におけるハウスダストダニアレルギー治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

ハウスダストダニアレルギーの概要

治療薬の開発

  • ハウスダストダニアレルギー向けパイプライン製品:概要
  • ハウスダストダニアレルギー向けパイプライン製品:比較分析

ハウスダストダニアレルギー:開発中の治療薬:企業別

ハウスダストダニアレルギー:開発中の治療薬:大学・研究機関別

ハウスダストダニアレルギー:パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

ハウスダストダニアレルギー:開発中の製品:企業別

ハウスダストダニアレルギー:開発中の製品:大学・研究機関別

ハウスダストダニアレルギー:治療薬開発に従事している企業

  • ALK-Abello A/S
  • Anergis SA
  • Biomay AG
  • Circassia Pharmaceuticals Plc
  • DBV Technologies S.A.
  • HAL Allergy BV
  • Stallergenes S.A.

ハウスダストダニアレルギー:治療薬の評価

  • 単剤治療薬
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • AllerDM
  • Allergen for House Dust Mite Allergy
  • Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis
  • BM-35
  • MK-8237
  • PL-103
  • STG-320
  • Vaccine for Allergic Rhino-Conjunctivitis and House Dust Mite Allergy
    • 製品概要
    • 作用機序
    • R&Dの進捗

最新のパイプライン動向

休止中のプロジェクト

開発中止の製品

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7615IDB

Summary

Global Markets Direct's, 'House Dust Mite Allergy - Pipeline Review, H1 2016', provides an overview of the House Dust Mite Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for House Dust Mite Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy
  • The report reviews pipeline therapeutics for House Dust Mite Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved House Dust Mite Allergy therapeutics and enlists all their major and minor projects
  • The report assesses House Dust Mite Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for House Dust Mite Allergy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for House Dust Mite Allergy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding House Dust Mite Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • House Dust Mite Allergy Overview
  • Therapeutics Development
    • Pipeline Products for House Dust Mite Allergy - Overview
  • House Dust Mite Allergy - Therapeutics under Development by Companies
  • House Dust Mite Allergy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • House Dust Mite Allergy - Products under Development by Companies
  • House Dust Mite Allergy - Companies Involved in Therapeutics Development
    • ALK-Abello A/S
    • Anergis SA
    • Biomay AG
    • Circassia Pharmaceuticals Plc
    • HAL Allergy BV
    • Stallergenes S.A.
  • House Dust Mite Allergy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AllerDM - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BM-35 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Epsi-Gam - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PL-103 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STG-320 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for House Dust Mite Induced Allergic Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • House Dust Mite Allergy - Recent Pipeline Updates
  • House Dust Mite Allergy - Dormant Projects
  • House Dust Mite Allergy - Discontinued Products
  • House Dust Mite Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Jan 27, 2016: Marketing authorization for ACARIZAX issued in France
      • Dec 09, 2015: New product (ACARIZAX) for treatment of house dust mite allergic rhinitis and asthma obtains reimbursement in Denmark
      • Nov 26, 2015: New medicine for house dust mite allergic rhinitis now available in Japan
      • Nov 19, 2015: Desensitization Therapy Actair House Dust Mite Sublingual Tablets Launched in Japan
      • Jun 09, 2015: ALK's partner, MSD, publishes Phase II data on house dust mite SLIT-tablet in leading allergy journal
      • Jun 04, 2015: ALK announces top-line results from its partner MSD's North American Phase III trial of house dust mite SLIT-tablet
      • Jun 16, 2014: ALK's Partner for Japan Announces Trial Results for House Dust Mite SLIT-Tablet
      • Jun 13, 2014: Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study
      • Mar 20, 2014: ALK's Partner Merck Initiates Phase III Clinical Development Programme in North America with the New Allergy Immunotherapy Tablet
      • Mar 20, 2014: House dust mite SLIT-tablet enters Phase III clinical development
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for House Dust Mite Allergy, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • House Dust Mite Allergy - Pipeline by ALK-Abello A/S, H1 2016
  • House Dust Mite Allergy - Pipeline by Anergis SA, H1 2016
  • House Dust Mite Allergy - Pipeline by Biomay AG, H1 2016
  • House Dust Mite Allergy - Pipeline by Circassia Pharmaceuticals Plc, H1 2016
  • House Dust Mite Allergy - Pipeline by HAL Allergy BV, H1 2016
  • House Dust Mite Allergy - Pipeline by Stallergenes S.A., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • House Dust Mite Allergy Therapeutics - Recent Pipeline Updates, H1 2016
  • House Dust Mite Allergy - Dormant Projects, H1 2016
  • House Dust Mite Allergy - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for House Dust Mite Allergy, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top